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Proteins trafficking through the secretory path-
way must first exit the endoplasmic reticulum
(ER) through membrane vesicles created and
regulated by the COPII coat protein complex.
Cranio-lenticulo-sutural dysplasia (CLSD) was
recently shown to be caused by amissensemu-
tation in SEC23A, a gene encoding one of two
paralogous COPII coat proteins. We now eluci-
date the molecular mechanism underlying this
disease. In vitro assays reveal that the mutant
form of SEC23A poorly recruits the Sec13-
Sec31 complex, inhibiting vesicle formation.
Surprisingly, this effect is modulated by the
Sar1 GTPase paralog used in the reaction, indi-
cating distinct affinities of the two human Sar1
paralogs for the Sec13-Sec31 complex. Patient
cells accumulate numerous tubular cargo-con-
taining ER exit sites devoid of observable mem-
brane coat, likely representing an intermediate
step in COPII vesicle formation. Our results indi-
cate that the Sar1-Sec23-Sec24 prebudding
complex is sufficient to form cargo-containing
tubules in vivo, whereas the Sec13-Sec31 com-
plex is required for membrane fission.
INTRODUCTION
The eukaryotic secretory pathway is critical for maintaining
membrane homeostasis and proper protein localization
within cells and is responsible for secretion of extracellular
factors necessary for developmental processes. Entrance
into the secretory pathway occurs at the endoplasmic
reticulum (ER), where proteins destined for the cell surface
or other organelles are incorporated into vesicles that bud
from ER membranes. The COPII protein coat is involved in
the majority, and possibly all, of these budding events by
providing the means for membrane deformation as wellDevelopmeas incorporation of integral membrane cargo into nascent
vesicles (Barlowe et al., 1994; Lee et al., 2004).
COPII coat formation is initiated by the small GTPase
Sar1, which is recruited to smooth ER membranes by
the GTP/GDP exchange factor Sec12 (Barlowe and
Schekman, 1993; Nakano and Muramatsu, 1989). GTP-
bound Sar1 then recruits the Sec23-Sec24 protein com-
plex to form a ‘‘prebudding’’ complex capable of engaging
cargo via interactions between Sec24 and the cytosolic
tails of transmembrane proteins (Aridor et al., 1998; Kuehn
et al., 1998; Miller et al., 2003; Mossessova et al., 2003).
Finally, the Sec13-Sec31 complex is recruited to promote
coat polymerization, membrane curvature, and mem-
brane fission (Aridor et al., 1998; Fath et al., 2007; Salama
et al., 1993; Stagg et al., 2006). Sec23 possesses GTPase-
activating protein (GAP) activity, stimulated by Sec13-
Sec31, catalyzing hydrolysis of Sar1-bound guanosine
triphosphate (Antonny et al., 2001; Yoshihisa et al., 1993).
The resultant Sar1-GDP has a much reduced affinity for
the Sec23-Sec24 complex, leading to coat dissociation
some time after vesicle budding.
To date, two human diseases have been found to result
from disruption of COPII genes. Chylomicron-retention
disease (CMRD), a fat malabsorption disease in which
enterocytes fail to secrete large lipoprotein particles into
the bloodstream, is caused by missense substitutions in
SAR1B, one of two paralogous Sar1 proteins in humans
(Jones et al., 2003). Cranio-lenticulo-sutural dysplasia
(CLSD) is a syndrome characterized by facial dysmor-
phisms, skeletal defects, late-closing fontanels, and cata-
racts (Boyadjiev et al., 2003). This developmental disease
was shown to arise from a missense substitution (F382L)
in SEC23A, one of two Sec23 paralogs in humans, result-
ing in disturbed ER-to-Golgi trafficking (Boyadjiev et al.,
2006). Not surprisingly, nonsense mutations in Sec23
were also found to have serious developmental conse-
quences in worms and fish (Lang et al., 2006; Roberts
et al., 2003). It remains unresolved how a missense muta-
tion in a single COPII paralog—SAR1B in the case of
CMRD; SEC23A in the case of CLSD—is sufficient to
cause disease.
To determine the effect of the perturbation induced
by the CLSD mutation, we have purified recombinantntal Cell 13, 623–634, November 2007 ª2007 Elsevier Inc. 623
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COPII Mutation Disrupts Coat but Not Cargo SortingFigure 1. F382L-SEC23A Is Not Compe-
tent for Budding of Cargo-Containing
Vesicles In Vitro When Paired with
SAR1B
(A) Permeabilized NIH 3T3 cells were incu-
bated with an ATP-regenerating system (ATPr),
GTP, rat liver cytosol, and purified recombinant
human COPII proteins as indicated. Rat liver
cytosol served as a source of COPII proteins
at 4 mg/ml. At 1 mg/ml cytosol, the reaction
was dependent upon the addition of purified
human COPII proteins. SAR1A and SAR1B
are the two known Sar1 paralogs in humans.
Isolated vesicle fractions were subjected to im-
munoblot analysis to detect the presence of
the resident ER protein Ribophorin-I and the
COPII cargo protein ERGIC-53/LMAN-1/p58.
(B) Protein sequence alignment of human
SAR1A and SAR1B. Identical residues are indi-
cated by and asterisk (*) and similar residues
are indicated by a colon (:) or a period (.) (very
similar, or somewhat similar). Those residues
differing significantly in charge or character
are highlighted in boldface and colored green.F382L-SEC23A and studied its behavior in vitro. We have
also performed morphological studies of primary skin
fibroblasts isolated from affected patients (Boyadjiev
et al., 2006). In this study, we have characterized the pre-
cise nature of the CLSD defect. We have established that
the F382L substitution interferes with recruitment of the
complete COPII protein coat. Furthermore, taking advan-
tage of differing behavior in vitro between the two Sar1
paralogs, we have identified a putative Sec13-Sec31
binding site at the interface of the Sar1-Sec23 complex.
In addition to providing the molecular basis for CLSD,
this study sheds light upon the interaction between the
Sec13-Sec31 complex and the Sar1-Sec23-Sec24 pre-
budding complex (now structurally characterized in an
accompanying report [Bi et al., 2007, in this issue]). Utiliz-
ing the COPII defect present in CLSD patient cells, we
have been able to distinguish the role of the prebudding
complex from that of the Sec13-Sec31 complex. Indeed,
the SEC23A-F382L mutation led to a striking proliferation
of tubular ER exit sites devoid of observable coat that are
nevertheless enriched with COPII cargo.
RESULTS
F382L-SEC23A Loss of Function Is Dependent
upon SAR1 Paralog
In our previous work (Boyadjiev et al., 2006), we demon-
strated F382L-SEC23A was incapable of supporting ER-
derived vesicle formation in vitro. In that work, we utilized
SAR1B as the source of Sar1 in the budding reaction. Sur-
prisingly, the other human paralog, SAR1A, partially res-
cued the in vitro defect exhibited by F382L-SEC23A624 Developmental Cell 13, 623–634, November 2007 ª2007 E(Figure 1A). In this assay, ER membranes prepared by dig-
itonin permeabilization of NIH 3T3 cells were incubated
with purified recombinant human COPII proteins and
a small amount of rat liver cytosol (required to supply an
unknown activity). After incubation at 30C, vesicles
were separated from the donor membranes by differential
centrifugation and analyzed by immunoblot. We assessed
the presence of the resident ER protein Ribophorin-I as
a negative control and the cargo receptor ERGIC-53 as
a model COPII cargo. Successful incorporation of ER-
GIC-53 into the vesicle fraction was achieved by adding
4 mg/ml rat liver cytosol, which provided COPII activity
at this concentration. Alternatively, the reaction was de-
pendent upon addition of purified COPII proteins if only
1 mg/ml rat liver cytosol was used.
Under these conditions, we compared the activity of
F382L-SEC23A and wild-type SEC23A (each in complex
with SEC24D) together with either SAR1A or SAR1B. The
level of ERGIC-53 found in the vesicle fraction of a reaction
containing F382L-SEC23A and SAR1B (2% budding effi-
ciency) was lower than without any added SEC23A, con-
firming our previously reported results. However, when
F382L-SEC23A was instead paired with SAR1A, the
amount of ERGIC-53 present in the vesicle fraction (17%
budding efficiency) was significantly above the back-
ground level (9% budding efficiency), although not as
much as with wild-type SEC23A (20% budding efficiency).
These results suggest that SAR1A can partially rescue the
defect associated with F382L-SEC23A. This effect was not
dependent upon the concentration of Sar1 used in the
reaction (data not shown and Figure 2D), and therefore
seemed instead to depend upon the physical propertieslsevier Inc.
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COPII Mutation Disrupts Coat but Not Cargo SortingFigure 2. F382L-SEC23A Failure to Recruit SEC13-SEC31A to Membranes Is the Cause of the Budding Defect
(A and B) GTPase-activity assay using synthetic liposomes performed at 37C essentially as described (Antonny et al., 2001; Futai et al., 2004). The
tryptophan fluorescence signal represents the conformational state of Sar1, owing to GTP or GDP binding. Starting with a sample containing synthetic
liposomes and GTP-loaded SAR1A (A) or SAR1B (B), wild-type (wt) or F382L-SEC23A-SEC24D was added and the subsequent decrease in signal
over time represents GTP hydrolysis. Where indicated, SEC13-SEC31A was added concurrently with wt or F382L-SEC23A-SEC24D. No cytosol was
included in these reactions.
(C) Liposome binding assay performed essentially as described (Kim et al., 2005; Matsuoka et al., 1998). The indicated COPII proteins were incubated
with synthetic liposomes at 37C for 20 min and then subjected to flotation on a sucrose density gradient. No cytosol was added to these reactions.
Input and float fractions were analyzed by 12% PAGE and stained with SYPRO-Red (Invitrogen).
(D) Quantitation of liposome binding experiments showing the ratio of SEC31A recruited to membranes in the presence of F382L-SEC23A versus
wild-type SEC23A, with SAR1A or SAR1B. Error bars are shown for 95% confidence levels calculated from five independent experiments.
(E) In vitro vesicle budding assay, similar to Figure 1A. Vesicle fractions from reactions with SAR1A are on the left and those from reactions with SAR1B
are on the right. Amounts of SEC13-SEC31A, SAR1A, and SAR1B added to reactions are indicated.of each Sar1 paralog. We also employed the three other
human paralogs of Sec24 (SEC24A, SEC24B, and
SEC24C) paired with wild-type or F382L-SEC23A and as-
sayed for the presence of additional cargo proteins in ves-
icle fractions (APP and Sec22b), with similar results (data
not shown). SAR1A and SAR1B share 90% amino acid se-
quence identity (Figure 1B), making the difference in activ-
ity when paired with F382L-SEC23A all the more striking.DevelopmeThe F382L Substitution Interferes with
Recruitment of Sec13-Sec31 to the Membrane
To better understand the nature of the vesicle formation
defect associated with the CLSD mutation, we tested
the GTPase-activating protein (GAP) activity of F382L-
SEC23A compared to wild-type SEC23A using a trypto-
phan fluorescence-based assay performed with pure pro-
teins (Antonny et al., 2001; Futai et al., 2004). In this assay,ntal Cell 13, 623–634, November 2007 ª2007 Elsevier Inc. 625
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COPII Mutation Disrupts Coat but Not Cargo Sortingthe nucleotide-bound state of Sar1 is monitored by relative
fluorescence measurements, because Sar1-GTP trypto-
phan fluorescence is higher than that of Sar1-GDP due to
distinct conformational states adopted in each case. Start-
ing with a mixture of synthetic liposomes and GTP-loaded
SAR1A or SAR1B, addition of wild-type or F382L-SEC23A-
SEC24D resulted in similarly modest rates of hydrolysis of
SAR1-GTP to SAR1-GDP, as judged by a corresponding
decrease in fluorescence (Figures 2A and 2B).
It is known from studies with yeast proteins that the
Sec13-Sec31 complex stimulates the GAP activity of
Sec23-Sec24 on Sar1 (Antonny et al., 2001). We were
curious to see the effect of human SEC13-SEC31A on
the GAP activity of F382L-SEC23A. Surprisingly, we saw
very different effects depending on which SAR1 paralog
was used in the assay. In reactions with SAR1A, addition
of SEC13-SEC31A stimulated the GAP activity of wild-
type and F382L-SEC23A-SEC24D equally well (Figure 2A;
wild-type was stimulated from 8.53 104 s1 to 4.53103
s1; F382L was stimulated from 8.4 3 104 to 4.8 3 103
s1). In contrast, in reactions with SAR1B, SEC13-SEC31A
failed to stimulate the GAP activity of F382L-SEC23A-
SEC24D to the same extent as wild-type (Figure 2B;
wild-type was stimulated from 8.6 3 104 s1 to 3.0 3
103 s1; F382L was stimulated from 5.1 3 104 to 1.1 x
103 s1). Therefore, the stimulation of SEC23A GAP activ-
ity by SEC13-SEC31A is noticeably affected by the F382L
substitution when paired with SAR1B.
We have previously shown that SEC31A exhibited an
altered localization in CLSD patient cells, as observed
by immunofluorescence microscopy (Boyadjiev et al.,
2006). We therefore considered the possibility that
F382L-SEC23A is unable to recruit the Sec13-Sec31 com-
plex necessary for COPII coat polymerization. To test this
hypothesis, we performed liposome floatation assays
(Kim et al., 2005; Matsuoka et al., 1998) to measure the
amount of Sec13-Sec31 complex bound to membranes
in the presence of F382L-SEC23A. Purified recombinant
human COPII proteins were incubated with synthetic lipo-
somes and the nonhydrolyzable GTP analog GTPgS at
37C for 20 min and applied to the bottom of a sucrose
density gradient. After a brief high-speed centrifugation
step, floated liposomes were isolated from the top of the
sucrose gradient and the COPII proteins present in the
liposome fraction were analyzed by SDS-PAGE (Fig-
ure 2B). Our previous study demonstrated the F382L-
SEC23A-SEC24D complex was competent to bind mem-
branes in the presence of SAR1B (Boyadjiev et al., 2006).
Here we monitored SEC13-SEC31A binding to wild-type
or F382L-SEC23A-SEC24D in the presence of SAR1A or
SAR1B. In the presence of SAR1B, there was a significant
decrease in the amount of SEC31A bound in reactions
with F382L-SEC23A compared to wild-type (Figure 2B,
lanes 7 and 8). This result suggests that the F382L substi-
tution interferes with recruitment of the SEC13-SEC31A
complex to the SAR1B-SEC23A-SEC24D membrane-
bound complex. A similar effect was seen if SAR1A was
included in the reaction instead of SAR1B (Figure 2B,
lanes 11 and 12). In addition, the mutant SEC23A-626 Developmental Cell 13, 623–634, November 2007 ª2007 ESEC24D complex was sometimes seen to be recruited
to membranes more robustly than the wild-type complex.
In order to more clearly examine the differences ob-
served between SAR1A and SAR1B binding reactions,
we compared the amounts of SEC31A in the membrane
fractions (normalized to the amount of bound SEC23A)
as a ratio of the quantity bound to F382L-SEC23A-
SEC24D versus wild-type SEC23A-SEC24D (Figure 2C)
in five independent experiments. Contrasting this ratio be-
tween SAR1A and SAR1B binding reactions, it appeared
that SAR1A partially mitigated the SEC13-SEC31A re-
cruitment defect exhibited by F382L-SEC23A with
SAR1B. It should be noted that the amount of SEC31A
bound in a reaction with SAR1A and F382L-SEC23A
was still below that of wild-type SEC23A. These binding
data correlate with the results of the in vitro vesicle forma-
tion and GAP assays, suggesting inhibition of Sec13-
Sec31 binding is responsible for the observed in vitro bud-
ding defect, although the difference between SAR1A and
SAR1B in the vesicle formation reaction and GAP assays
is more dramatic than in the liposome binding assay.
In order to determine if the observed reduction in
SEC13-SEC31A recruitment to membrane-bound F382L-
SEC23A-SEC24D was the cause of the vesicle budding
defect, we returned to the in vitro vesicle formation assay.
We reasoned that addition of excess SEC13-SEC31A to
the vesicle formation assay might overcome, by mass ac-
tion, the diminished F382L-SEC23A activity. When 60 mg/
ml SEC13-SEC31A (6-fold more than used previously)
was added to a reaction containing SAR1B and F382L-
SEC23A, the amount of ERGIC-53 incorporated into the
vesicle fraction was restored to the level seen in reactions
with wild-type SEC23A (Figure 2D, right half). This larger
amount of SEC13-SEC31A did not support budding of
ERGIC-53-containing vesicles in the absence of SEC23A-
SEC24D, indicating the restored activity seen with F382L-
SEC23A was due to a mass action effect. Similar results
were also observed in reactions utilizing different Sec24 pa-
ralogs and detecting other cargo proteins (data not shown).
Addition of excess SAR1B to the reaction did not increase
the amount of ERGIC-53 found in the vesicle fraction, and
together with F382L-SEC23A, actually suppressed the
background level. This result might be explained as a titra-
tion of the small amount of wild-type COPII proteins pres-
ent in the cytosol added to the reactions.
The same complementation phenomenon was ob-
served with SAR1A (Figure 2D, left half), in which the level
of ERGIC-53 found in the vesicle fraction of the F382L-
SEC23A reaction with excess SEC13-SEC31A was re-
stored to that seen with wild-type SEC23A. Furthermore,
in the GAP activity assay, addition of several-fold excess
SEC13-SEC31A over F382L-SEC23A-SEC24D resulted
in stimulation of GAP activity to the same extent as with
wild-type SEC23A-SEC24D (data not shown). Taken
together with the liposome binding and immunocyto-
chemistry results, the results from these functional assays
establish that the observed F382L-SEC23A vesicle forma-
tion defect arises from a reduced affinity for the Sec13-
Sec31 complex.lsevier Inc.
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COPII Mutation Disrupts Coat but Not Cargo SortingFigure 3. Calvarial Osteoblasts Express
Little SEC23B
Postnuclear cultured cell lysates (A) or normal
human tissue lysates (B) were analyzed by im-
munoblot, using antibodies specific for either
SEC23A or SEC23B, in addition to an antibody
recognizing both human Sec23 paralogs (a-
SEC23A/B), an antibody that recognizes both
human SAR1 paralogs (a-SAR1A/B), and an
antibody for actin as a loading control.
(A) Cultured cells used were HEK293T,
HEK293T transfected with a plasmid to over-
express SEC23A, PC-3, homozygous CLSD
patient skin fibroblasts, heterozygous CLSD
patient skin fibroblasts, and primary calavarial osteoblasts. On the right side, purified human proteins (20 ng SEC23A, 20 ng SEC23B, and 400 pg
SAR1A + 400 pg SAR1B) were loaded to demonstrate antibody specificity.
(B) Similar immunoblot of normal human tissue lysates (35 mg each lane, except for liver, 70 mg), as well as 3 ng SEC23A, 3 ng SEC23B, and 250 pg
SAR1A + 250 pg SAR1B. Asterisks denote species that we believe to be nonspecific crossreacting proteins, although spleen may contain a slower
migrating, modified form of SEC23A (visible in anti-SEC23A/B and anti-SEC23A treatments). As expected, muscle cells have a very high actin:COPII
ratio.Calvarial Osteoblasts Express Relatively
Low Levels of SEC23B
We sought to understand why only certain tissues seem to
be affected in CLSD patients, despite the essential role of
Sec23 in the secretory pathway. Many physiological pro-
cesses requiring an intact secretory pathway, such as di-
gestion and insulin signaling, are seemingly unaffected by
the F382L substitution in SEC23A. One explanation is that
the reduced activity of the CLSD mutant SEC23A protein
may be sufficient for COPII coat assembly in most cell
types, but it is problematic in tissues with higher secretory
burdens. In addition, based on our in vitro data, a high
level of SAR1B in comparison to SAR1A might exacerbate
the defect in certain cell types. Another possibility is that
the paralogous SEC23B protein might provide Sec23 func-
tion to complement the defect. Using antibodies we devel-
oped to discriminate between SEC23A and SEC23B, and
taking advantage of the gel-mobility difference between
SAR1A and SAR1B, we examined the relative expression
of these proteins in normal primary calvarial osteoblasts
in comparison to other cultured cell types. Calvarial oste-
oblasts are primarily responsible for ossification of the cra-
nial suture, an event that is almost absent in CLSD patients
(Boyadjiev et al., 2003). Strikingly, these cells express
very little SEC23B (Figure 3A, lane 6), suggesting that
SEC23B is unavailable to functionally compensate for
F382L-SEC23A in calvarial osteoblasts, but may do so in
phenotypically normal tissues of CLSD patients. In order
to address this possibility, we performed immunoblot
analysis on several normal human tissues (Figure 3B). Of
the five tissues tested, all five express detectable levels
of SEC23B. Although this is not an exhaustive analysis,
it supports the notion that the tissues affected in CLSD pa-
tients are those lacking sufficient SEC23B expression.
The antibody used to recognize SAR1A and SAR1B dis-
plays much higher avidity to SAR1B, judging by the signals
obtained when equal amounts of recombinant SAR1A and
SAR1B proteins were probed simultaneously (Figure 3,
lane 9). Therefore, the level of SAR1A is much higher
than SAR1B in calvarial osteoblasts (Figure 3, lane 6).DevelopmeTaken together, these results suggest that low SAR1A
expression in calvarial osteoblasts is not the source of
the cranial suture phenotype in CLSD patients, but instead
the cause is likely the low level of SEC23B expressed in
this cell type. It remains possible that low SAR1A expres-
sion in certain tissues may contribute to other develop-
mental problems associated with CLSD.
CLSD Patient Fibroblasts Accumulate Tubular
Profiles Lacking an Observable Coat
In order to analyze the cellular phenotype caused by the
F382L-SEC23A substitution, we examined CLSD patient
skin fibroblasts by thin-section electron microscopy and
discovered a surprising abundance of tubular extensions
projecting from distended peripheral ER compartments
(Figure 4A), which were virtually absent in micrographs of
heterozygote control cells. In some homozygous mutant
cells, we observed a very large number of tubulo-vesicular
elements within a small area of the ER (see Figure S1 in the
Supplemental Data available with this article online), an oc-
currence never observed in heterozygote or wild-type con-
trol cells. In comparison to peripheral budding profiles in
wild-type (data not shown) and phenotypically normal het-
erozygote cells (Figures 4B–4D), the tubular extensions
observed in homozygote mutant cells were virtually devoid
of an observable coat on the cytosolic membrane surface
(Figure 4E and Table 1). The same phenomenon was also
observed at transitional ER sites proximal to the cis-Golgi
complex (Figure S2 and Table 1). In rare instances, a cyto-
solic coat could be observed on ER budding profiles in
homozygote mutant cells. In such cases, the coat was ob-
served at the tip of tubules connected to the ER (Figure 4F)
or on simple budding profiles (Figure 4G).
We performed quantitative immunocytochemistry on
primary skin fibroblasts isolated from homozygous
(F382L/F382L) CLSD patients to determine if a reduction
of Sec13-Sec31 binding to ER exit sites (ERES) could be
observed in vivo. We treated thin sections with anti-
SEC31A antibody and gold-labeled secondary antibody
and counted the number of gold particles found perntal Cell 13, 623–634, November 2007 ª2007 Elsevier Inc. 627
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COPII Mutation Disrupts Coat but Not Cargo SortingFigure 4. Peripheral ER Exit Sites Are Numerous in CLSD Patient Cells
(A) Thin-section electron micrograph of a homozygote mutant cell in the region of ER. Note the many tubular protrusions (arrows) projecting from
swollen ER compartments.
(B–D) ER exit sites in heterozygous (unaffected) cells showing the COPII coat on the cytosolic membrane surface of tubules. Budding profiles
assumed a variety of shapes, including constricted tubules. Note also the thin morphology of the ER compartments from which the tubules project.
(E–G) Typical ER exit site in a homozygous mutant (affected) cell, in which the tubules exhibited no obvious membrane coat. In10% of cases, coated
surfaces were observed on tubular ER exit sites in homozygous mutant cells (see Table 1), but then only at the tip of a tubule (F) or on simple budding
profiles (G).tubular profile. In the mutant cells there was a significant
reduction in the number of SEC31A-positive tubules
observed compared to the heterozygote and wild-type
controls (Figure S3). Therefore, the F382L substitution ap-
pears to impair Sec13-Sec31 recruitment to ER mem-
branes in vivo as well as in vitro. The lack of an observable
coat in mutant cells is consistent with the reduced SEC31A
immunogold labeling of ER exit sites in these cells. In con-
trast, when we performed immunogold analysis with anti-
Sar1 antibody, we observed a marked increase in Sar1
labeling at ERES in patient cells compared to unaffected628 Developmental Cell 13, 623–634, November 2007 ª2007 Eheterozygotes (Figure 5). The F382L substitution therefore
results in accumulation of Sar1 at ERES in vivo.
Sorting of COPII Cargo into ER Exit Sites
Is Unaffected in CLSD Patient Fibroblasts
We were curious to observe the steady-state localization
of COPII cargo in patient cells, given the marked prolifer-
ation of uncoated ER exit sites. We therefore examined
cells stained with a monoclonal antibody for ERGIC-53/
LMAN-1/p58, a secretory cargo receptor that cycles be-
tween the ER and cis-Golgi compartments (Nichols et al.,lsevier Inc.
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COPII Mutation Disrupts Coat but Not Cargo SortingTable 1. Quantitation of Coated Budding Profiles in Thin-Section Electron Micrographs
Budding Profiles in Peripheral ER Exit Sites
Cell type
Total Budding
Profiles Examined
Percentage Of Coated
Profiles Images Analyzed
Homozygous mutant
(affected)
477 10% 40
Heterozygous
(unaffected)
22 100% 20
Unrelated wild-type 23 100% 20
Budding Profiles in ER Exit Sites Near the cis-Golgi (Transitional Elements)
Cell Type
Total Budding
Profiles Examined
Percentage of Coated
Profiles
Transitional Elements
Analyzed
Homozygous mutant
(affected)
72 11% 30
Heterozygous
(unaffected)
44 88% 30
Unrelated wild-type 37 100% 301998; Saraste and Svensson, 1991; Schindler et al., 1993).
ERGIC-53 staining is thought to represent ER exit sites,
the ERGIC, the cis-Golgi, and vesicular-tubular clusters
(VTCs) transiting to the cis-Golgi (Ben-Tekaya et al., 2005;
Presley et al., 1997; Scales et al., 1997). We noticed a sig-
nificant accumulation in homozygous mutant cells of ER-
GIC-53-positive punctae in the peri-nuclear region and
periphery of cells (Figures 6A and 6C). These punctae were
more numerous and more intensely stained than the more
typical ERGIC-53-containing structures found in control
cells (Figures 6B and 6D). Costaining with an antibody
for the lumenal ER marker PDI revealed ERGIC-53 punc-
tae localized proximally to PDI-filled ER distensions (Fig-
ures 6E and Figure S4). Closer examination revealed that
ERGIC-53 is present in dot-like structures adjacent to,
but distinct from, swollen ER cisternae containing PDI
(Figures 6F–6H, and Figure S4). These structures veryDevelopmenlikely correspond to the numerous tubular ER exit sites we
observed by thin-section electron microscopy (Figure 4).
Seeking a higher resolution view, we next performed anti-
ERGIC-53 immunocytochemistry on fixed thin sections of
CLSD patient skin fibroblasts. Tubular ER protrusions
were specifically decorated withgoldparticles, and labeling
was virtually absent from dilated ER cisternae, indicating
enrichment of ERGIC-53 at ER-exit sites (Figure 6I). This
result confirms the peripheral ERGIC-53 punctae we ob-
servedby immunofluorescence correspond toERexit sites.
We have therefore established that CLSD patient cells ac-
cumulate COPII cargo at steady state, and membrane pro-
tein cargo is specifically localized to numerous tubular ER
exit sites virtually devoid of observable cytoplasmic coat.
These structures may represent an intermediate step in
COPII carrier formation, occurring after membrane protein
cargo capture but prior to completion of coat assembly.Figure 5. Sar1 Is Enriched at ER Exit Sites in CLSD Patient Cells
Thin sections were analyzed by immunoelectron microscopy using anti-Sar1 antibody and gold-labeled secondary antibody. The average number of
gold particles per tubular-vesicular profile is given with standard errors. The number of images evaluated is in parentheses. * p < 0.001 for homozygote
versus heterozygote and unrelated wild-type (Student’s t-test).tal Cell 13, 623–634, November 2007 ª2007 Elsevier Inc. 629
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COPII Mutation Disrupts Coat but Not Cargo SortingFigure 6. Sorting of the COPII Cargo ERGIC-53 into ER Exit Sites Is Unaffected in CLSD Patient Cells
(A–D) Confocal immunofluorescence images of anti-ERGIC-53 staining in primary skin fibroblasts from affected homozygotes (A and C) and unaf-
fected heterozygotes (B and D). (C) and (D) are magnifications of (A) and (B), respectively.
(E) Confocal immunofluorescence image of anti-ERGIC-53 (green) and anti-PDI (red) staining of an affected homozygote cell.
(F–H) Magnification of the framed area in (E). The PDI-positive structures are distended ER compartments. The ERGIC-53-positive structures are
located proximally to, but not colocalized with, the ER distensions and correspond to the tubular ER exit sites seen in Figure 4.
(I) Thin sections were analyzed by immunoelectron microscopy using an anti-ERGIC-53 antibody and gold-coupled secondary antibody. Gold
particles concentrate in tubular ER exit sites and are virtually absent in distended ER cisternae.DISCUSSION
The mechanisms behind genetic diseases are usually
quite complex, involving misfunction or dysregulation of
several genes. Even for those diseases in which only a sin-630 Developmental Cell 13, 623–634, November 2007 ª2007 Egle gene is thought to be involved, such as CLSD, under-
standing how genotype leads to phenotype can be prob-
lematic when the gene involved is poorly understood.
Here we have been able to ascertain the molecular basis
for CLSD based on in vitro analysis of the effects of thelsevier Inc.
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tured primary cells from patients. Furthermore, our work
has uncovered a remarkable cellular phenotype shedding
light on the role of the prebudding complex in the forma-
tion of ER exit sites.
Basis of the CLSD Cellular Phenotype
In order to understand the root cause of the ER export de-
fect observed in CLSD patient cells, we compared F382L-
SEC23A to wild-type SEC23A in several in vitro assays.
F382L-SEC23A is able to bind to synthetic membranes
at a level equivalent to wild-type and retains intrinsic
GAP activity similar to wild-type protein (Figure 2). How-
ever, F382L-SEC23A shows reduced recruitment of the
Sec13-Sec31 outer coat complex both in vitro and in
vivo (Figure 2 and Figure S3), especially when paired
with SAR1B (Figures 1A, 2B, and 2D). We found that the
in vitro budding defect observed with F382L-SEC23A
can be ameliorated by addition of more SEC13-SEC31A
complex. Taken together, these results establish that weak
Sec13-Sec31 binding to F382L-SEC23A is the cause of the
budding defect and, by extension, of the cellular CLSD
phenotype.
CLSD is characterized by open calvarial sutures with
large, late-closing fontanels (the ‘‘soft-spot’’ on the skull
found on newborns), sutural cataracts, facial dysmor-
phisms, and skeletal defects. To begin to address why
certain tissues are affected in CLSD patients, we looked
at the levels of SEC23A and SEC23B in primary calvarial
osteoblasts (Figure 3). These cells, found on the skullcap,
are responsible for membraneous ossification of the fon-
tanels. We observed a very low level of SEC23B in calva-
rial osteoblast lysates, suggesting these cells are specifi-
cally affected because of insufficient SEC23B protein
available to provide normal Sec23 function. Conversely,
unaffected tissues in CLSD patients might retain normal
function through expression of sufficient SEC23B to
complement the loss of SEC23A function. Analysis of sev-
eral normal human tissues showed detectable levels of
SEC23B, providing evidence in support of this idea. The
primary skin fibroblasts from CLSD patients we examined
also expressed low levels of SEC23B, explaining the
morphological ER defects we observe in these cells. It
should be noted that there is no obvious skin defect asso-
ciated with CLSD, so it seems skin fibroblasts remain
functional despite an altered ER morphology in CLSD
patients.
COPII Function at ER Exit Sites
One might have expected to observe a complete absence
of ER exit sites in CLSD patient cells because of impaired
COPII function stemming from mutant SEC23A. Our bio-
chemical analysis revealed that the main effect of this mu-
tation is to limit the recruitment of the Sec13-Sec31 com-
plex by the Sar1-Sec23-Sec24 prebudding complex,
allowing us to separate the roles of these two protein com-
plexes in the formation of ER exit sites. We have observed
a proliferation of Sar1-enriched tubular ER exit sites pro-
truding from distended ER compartments (Figures 4 andDevelopme5, and Figure S1), and the COPII cargo ERGIC-53 is being
properly sorted to these ER exit sites (Figure 6 and
Figure S4). These results suggest that the prebudding
complex is sufficient to generate tubular extensions at
ER exit sites and to sort COPII cargo. Accordingly, the role
of the Sec13-Sec31 complex is to fragment these tubular
extensions into transport vesicles.
This interpretation is compatible with previous reports
that Sar1 is able to tubulate ER membranes and to sort
cargo in the absence of COPII function. This mechanism
was proposed as the result of a study utilizing a permeabi-
lized cell system, in which addition of a GTP-locked mu-
tant (H79G) form of Sar1 led to the formation of extended
ER tubules enriched in COPII cargo and visible by light mi-
croscopy (Aridor et al., 2001). These structures formed
without addition of other COPII proteins but were capable
of recruiting Sec23 from cytosol added subsequently. To
our knowledge, no similar structures (produced by Sar1
without contribution from other COPII proteins) have
been observed in vivo. In contrast, based upon our bio-
chemical data demonstrating that F382L-SEC23A is effi-
ciently recruited to membranes by Sar1, it is likely that
the tubules we observe in CLSD patient cells are deco-
rated by Sar1-F382L-SEC23A-Sec24 prebudding com-
plexes. This would be expected given the role of the
Sec13-Sec31 complex in stimulating GTP hydrolysis of
Sar1-GTP, a prerequisite for coat dissociation from the
membrane (Antonny et al., 2001). Our observation of
increased Sar1 labeling at ERES in patient cells (Figure 5)
is consistent with this notion. It is possible that these com-
plexes are not large enough or are too dispersed to be ob-
served as a coat by electron microscopy (Figure 4 and Fig-
ure S2). In either case, the failure to recruit Sec13-Sec31
(Figure S3) likely accounts for the lack of observable mem-
brane coat. Our results therefore provide insight into the
mechanisms underlying ER tubulation and vesiculation
in vivo.
Implications for COPII Coat Protein Assembly
The F382L-substitution, although occurring at a conserved
position in primary sequence, is subtle, maintaining the
hydrophobic character of the original residue. The human
F382L-SEC23A protein retains many aspects of wild-type
function, including Sec24 binding, membrane binding,
and intrinsic GAP activity (Figure 2). We found that the
equivalent substitution in yeast Sec23p (F380L) had no
obvious functional consequence (Supplemental Data
and Figure S5), underlining the subtle nature of this
change. Accordingly, the structural perturbation induced
by the F382L substitution in human SEC23A appears to
be quite local in nature, as the only functional conse-
quences relate to Sec13-Sec31 binding. This suggests
that F382 should occupy, or be very near to, a Sec13-
Sec31 binding site on Sec23. Furthermore, the effect of
the F382L substitution on Sec13-Sec31 binding is modu-
lated by the identity of the Sar1 paralog (Figures 1 and 2),
presumably because of higher affinity of SEC13-SEC31A
for SAR1A than for SAR1B. Thus, Sec13-Sec31 may
bind to Sar1 at a site comprising at least one residuental Cell 13, 623–634, November 2007 ª2007 Elsevier Inc. 631
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imal to the CLSD Mutation and Residues
of Sar1 That Differ between Homologs
Atomic structure of a fragment of yeast Sec31
(cyan) in complex with Sar1p (red) and Sec23p
(orange) (Bi et al., 2007), with Sec24p (light
green) included based on the structure of the
Sar1p-Sec23p-Sec24p pre-budding complex
(Bi et al., 2002). The membrane binding surface
of this complex is thought to lie underneath this
perspective. The position of the yeast residue
equivalent to human F382 (F380) is indicated
by blue coloring of several residues surround-
ing position 380 in primary sequence, and by
the label ‘‘F382L.’’ The eight residues of human
Sar1 that are significantly different in chemical
composition between SAR1A and SAR1B (as
shown in Figure 1B) are highlighted in dark
green. All eight of these residues lie on the glob-
ular surface of Sar1, and six of them are on the
same face of the complex as is F380. In partic-
ular, residues corresponding to positions 80,
113, 116, and 117 in human Sar1 appear capa-
ble of making direct contact with Sec31.that is distinct between SAR1A and SAR1B. A new crystal
structure of the complex between yeast Sar1p, Sec23p,
and a fragment of Sec31p (Bi et al., 2007) corroborates
both of these predictions arising from our biochemical
data. F382 is not itself surface exposed, but lies buried
just beneath the surface of Sec23 as part of a surface
helix. The Sec31 fragment makes direct contact with this
helix, and additional contacts are made between Sec31
and Sar1 in the vicinity of several residues whose identity
differs between SAR1A and SAR1B, specifically, residues
equivalent to positions 80, 113, 116, and 117 in human
SAR1 (Figure 7).
Our suggestion that SEC13-SEC31A has a higher affin-
ity for SAR1A than for SAR1B has further implications for
COPII vesicle formation. Within the cellular milieu, the rep-
ertoire of COPII paralogs available for coat polymerization
should dictate the nature of the vesicles budding from the
endoplasmic reticulum. It has been assumed that in differ-
ent tissues, differential expression of COPII paralogs
would confer distinct properties to vesicles according to
the requirements of ER export, most simply in the case of
distinct cargos selected by Sec24 paralogs (Miller et al.,
2002; Tang et al., 1999; Wendeler et al., 2007). Here we
have provided the first evidence for distinct affinities be-
tween COPII subunit paralogs, suggesting that variation
of Sar1 paralog expression is another means of regulation.
Human genetic evidence has implicated SAR1B in for-
mation of ER-derived carriers larger than a typical 60–70
nm COPII vesicle (Jones et al., 2003). Accordingly, we
are tempted to speculate on a possible functional role for
the weaker affinity of SAR1B for SEC13-SEC31A in the for-
mation of larger COPII vesicles. Perhaps the Sec13-Sec31
cage (Fath et al., 2007; Stagg et al., 2006) is less con-
strained when in complex with SAR1B. This added flexibil-
ity might allow Sec13-Sec31 to assemble into larger caged
structures consistent with larger vesicles.632 Developmental Cell 13, 623–634, November 2007 ª2007 EEXPERIMENTAL PROCEDURES
Antibodies and Cell Culture
Anti-Ribophorin I serum was provided by Peter Walter. Anti-SEC23A/B
was provided by Jean-Pierre Paccaud (Pagano et al., 1999). Anti-
Sec22b was provided by Jesse Hay (Hay et al., 1996). Rabbit anti-
SEC31 was provided by A. Hubbard (Johns Hopkins University).
Monoclonal anti-PDI was a gift from S. Fuller (EMBL-Heidelberg).
Anti-ERGIC-53/LMAN-1/p58 antiserum used for immunoblots was
raised in rabbits injected with a purified GST fusion to residues 49-
484 of rat ERGIC-53/LMAN-1/p58 produced in E. coli. Monoclonal
anti-ERGIC-53/LMAN-1/p58 antibody was purchased from Alexis
Biochemicals. Anti-SAR1A/B antiserum was raised in rabbits injected
with a mixture of purified human SAR1A and SAR1B. Anti-SEC23A
antiserum was raised in rabbits injected with the peptide (CG)-SKVPL
TQATRGPQVQQPPPSNR conjugated to rabbit serum albumin. Anti-
SEC23B antiserum was raised in rabbits injected with the peptide
(CG)-TKPAMPMQQARPAQPQEHPFASSR conjugated to rabbit serum
albumin. Both of these peptide-derived antisera were purified using
peptide-conjugated Sulfolink beads (Pierce).
Cell lines were cultured and transfected using standard procedures.
Patient fibroblasts were cultured as described (Boyadjiev et al., 2006).
The calvarial osteoblast cell lysate was obtained from ScienCell
Research Laboratories. The tissue lysates were purchased from Clon-
tech (‘‘Protein Medleys’’).
Immunofluorescence and Electron Microscopy
Fibroblasts plated on glass coverslips were fixed with 4% PAF for
30 min and permeabilized with methanol at 20C for 3 min. Primary
antibodies used were polyclonal anti-ERGIC-53 (diluted 1:400), poly-
clonal anti-SEC31 (diluted 1:200), monoclonal anti-ERGIC-53 (diluted
1:4000), and monoclonal anti-PDI (diluted 1:20). Secondary antibodies
used were Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 546
goat anti-mouse IgG (diluted 1:400, Molecular Probes/Invitrogen).
After staining cells with the appropriate primary and secondary anti-
bodies, images were visualized and captured with a Zeiss LSM 510
confocal microscope (Carl Zeiss).
For electron microscopy analysis, we fixed confluent fibroblast cell
cultures with 2% glutaraldehyde in 0.1 M phosphate buffer and either
gently scraped before postfixation with osmium tetroxide, dehydration,
and embedding, or processed in situ. En bloc staining was performedlsevier Inc.
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we fixed cells with 2.5% glutaraldehyde and processed for cryo-ultra-
microtomy as described (Volchuk et al., 2000). Ultrathin frozen sections
were prepared and incubated for immunolabeling as described (Liou
et al., 1996).
Protein Expression and Purification
Human SAR1A and SAR1B proteins were overexpressed in E. coli and
purified as cleaved GST-fusions as described for hamster Sar1a (Kim
et al., 2005). SEC23A-hisSEC24D, F382L-SEC23A-hisSEC24D, and
SEC13-hisSEC31A were purified using immobilized metal affinity
chromatography from baculovirus-infected insect cells as described
(Boyadjiev et al., 2006; Kim et al., 2005).
In Vitro Vesicle Formation Assay
The in vitro vesicle budding assay was performed essentially as
described (Kim et al., 2005) in B880 buffer using semi-intact cells
permeabilized with digitonin (Plutner et al., 1992; Wilson et al., 1995)
and washed with B880 buffer containing 1M KOAc as a donor ER
membrane source.
GTPase Activity Assay
The tryptophan fluorescence GTPase activity assay was performed at
37C as described for yeast COPII proteins (Antonny et al., 2001; Futai
et al., 2004), using major-minor mix synthetic liposomes containing
10% cholesterol, in a stirred-cell cuvette. To 0.3 mM liposomes in
HKM buffer [20 mM HEPES (pH 7.2), 150 mM KOAc, 1 mM Mg(OAc)2],
we added SAR1A or SAR1B to a final concentration of 1.33 mM. One
minute later, GTP was added to 30 mM. After spontaneous exchange
of GDP for GTP was complete (another 10–15 min), wild-type or
F382L-SEC23A-SEC24D complex was added to 250 nM. Where indi-
cated, SEC13-SEC31A complex was added to 400 nM simultaneously
with wild-type or F382L-SEC23A-SEC24D.
Liposome Binding Assay
The liposome binding assay was performed as described for yeast
COPII proteins (Kim et al., 2005; Matsuoka et al., 1998) using 10% cho-
lesterol major-minor mix liposomes. Following a 20 min incubation at
37C, the protein-liposome mixture was separated by flotation through
a sucrose density step gradient (in HKM buffer) achieved by centrifu-
gation at 391,000 3 g for 25 min at 22C.
Supplemental Data
Supplemental data including Supplemental Experimental Procedures,
Supplemental References, and five Supplemental Figures can be
found online at http://www.developmentalcell.com/cgi/content/full/
13/5/623/DC1/.
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